The pharmaceutical industry is witnessing a major shift in diabetes treatment with the introduction of GLP-1 transdermal devices. These innovative delivery systems offer a possibly convenient option to needle injections for individuals dealing with diabetes mellitus type 2. By avoiding the need for frequent injections, GLP-1 patches promise to enha